Telomerase polypeptide vaccine for treating cancer
AssigneeUltimovacs ASA
InventorsGustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
Life of this patent
Estimating the term…
Abstract
A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
Claims15
A pharmaceutical composition comprising a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising a sequence selected from the group consisting of:
- i) SEQ ID NO:
- 1;
- and
- ii) the sequence of a fragment of i) comprising at least 20 amino acids,
- wherein the polypeptide is for eliciting a CD4+ and/or a CD8+ T-cell response and further comprises amino acids
- at the N and/or C termini that are different from those present in a naturally occurring telomerase enzyme,
- and wherein the pharmaceutical composition further comprises a pharmaceutically acceptable adjuvant, diluent or excipient.
A nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising a sequence selected from the group consisting of:
- i) SEQ ID NO:
- 1;
- and
- ii) the sequence of a fragment of i) comprising at least 20 amino acids, wherein the nucleotide sequence which encodes SEQ ID NO:
- 1 or the fragment thereof is different from that comprised within a naturally occurring human telomerase reverse transcriptase gene.
Dependencies are inferred from the claim text.